Currently, the amount of HIV/AIDs prevalence in different parts of Africa is tied to rape and sex work. Around Africa, the main tactic for mitigating AIDs is not medication, but increased access to condoms. The increased access to condoms in the community is helping but not as much as needed. Key populations and their sexual partners account for over half of the new HIV/AIDs cases in Africa. Key populations include men who have sex with men, people who inject drugs, people in prisons and other closed settings, sex workers and their clients, and transgender people.

HIV/AIDs assistance

Of the 38.6 million people living with HIV/AIDS globally, almost 25 million (65%) live in sub-Saharan Africa. In 2018 there were 470,000 deaths in Africa attributed to HIV/AIDs. In the United States in 2018 there were only 15,820 deaths attributed to HIV/AIDs. 

Boston University

Kerr DL.
J Sch Health. 1989 Oct;59(8):369-70. doi: 10.1111/j.1746-1561.1989.tb04749.x.
PMID: 2811319
https://pubmed.ncbi.nlm.nih.gov/?term=Kerr+DL&cauthor_id=2811319

HIV infection and AIDS in Africa and the Third World

Prevalence of HIV/AIDs in Africa

There are, at present, twenty-two anti-HIV drugs that have been formally licensed for clinical use in the treatment of HIV infections (AIDS): zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, tenofovir, nevirapine, delavirdine, efavirenz, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir. Only 64% of the people living with HIV/AIDs in Africa are able to access antiretroviral treatment. A large part of the problem is the people who are not yet diagnosed and don't know to access the medication treatments.

HIV/AIDs treatment

 Retrieved from https://cdn.rcsb.org/pdb101/learn/resources/structural-biology-of-hiv/index.html#:~:text=HIV (Human Immunodeficiency Virus) is,by a lipid bilayer membrane.


Learn Before

Related

Learn After